Results 151 to 160 of about 38,480 (291)

Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation

, 2013
The most significant complication of atrial fibrillation (AF) is thromboembolic stroke. Furthermore, the consequences of AF-related stroke tend to be more severe than those of other aetiologies.
Connelly, D.T., Lang, N.N.
core   +1 more source

Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 10, Page 638-653, October 2025.
ABSTRACT Background There are sparse data to guide resumption of direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation (AF) who survive a major gastrointestinal bleeding (GIB) event. Objective To compare the risk–benefit profile of restarting DOACs versus warfarin among patients with AF following hospitalization for ...
Oluwadolapo D. Lawal, Herbert D. Aronow, Fisayomi Shobayo, Yichi Zhang, Anne L. Hume, Tracey H. Taveira, Kelly L. Matson, Justin Gold, Xuerong Wen   +8 more
wiley   +1 more source

Contraception in Myeloproliferative Neoplasms: A Pharmacological Review

European Journal of Haematology, Volume 115, Issue 4, Page 344-348, October 2025.
ABSTRACT Myeloproliferative neoplasms (MPNs) are chronic hematologic disorders characterized by clonal proliferation of myeloid lineage cells, commonly driven by JAK2 mutations, and associated with significant thrombotic and hemorrhagic complications.
Awni Alshurafa, Maria Benkhadra, Anas M. Babiker, Wafa M. Mohammed, Mohamed A. Yassin   +4 more
wiley   +1 more source

Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE [PDF]

, 2013
Renato D. Lópes, David García, Daniel Wojdyla, Paul Dorian, John H. Alexander, Lars Wallentin, Fernando Laņas, Michael Hanna, Claes Held, Christopher B. Granger   +9 more
openalex   +1 more source

Immediate Leg Mobilization is Feasible After Catheter Ablation of Atrial Fibrillation Using Large Vascular Access Sheaths (Pulsed Field and Cryoballoon Ablation)

Journal of Cardiovascular Electrophysiology, Volume 36, Issue 10, Page 2539-2543, October 2025.
ABSTRACT Background Vascular recovery from catheter ablation (CA) has traditionally required a period of leg immobilization which can lead to discomfort and prolonged time to discharge. Objective The objective of this study was to compare a strategy of immediate leg mobilization (IM) using suture‐mediated closure devices against traditional vascular ...
Riya Sam, Romil Patel, Lavisha Singh, Westby Fisher, Mark Metzl, Jose Nazari, Alex Ro, Hany Demo, Jeremiah Wasserlauf   +8 more
wiley   +1 more source

Apixaban indications set to AMPLIFY? [PDF]

, 2013
Tim Geach
openalex   +1 more source

Antikoagulation bei Vorhofflimmern - Dabigatran, Rivaroxaban oder Apixaban - die Qual der Wahl? [PDF]

, 2013
Armin Luik, Claus Schmitt, Andrea Radzewitz   +2 more
openalex   +1 more source

Apixaban: Third oral anticoagulant to compete with warfarin [PDF]

, 2013
Maria G. Tanzi
openalex   +1 more source

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence

Drug Design, Development and Therapy, 2014
Ali Zalpour,1 Thein Hlaing Oo21Division of Pharmacy – Clinical Programs, 2Section of Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Anticoagulation with heparin and vitamin K ...
Zalpour A, Oo TH
doaj  

Clot time ratio (CTR) and treatment outcomes in Apixaban-treated atrial fibrillation patients

Scientific Reports
There are clinical situations where information about the anticoagulant effects of Apixaban could be useful. Specialised methods for measuring Apixaban concentrations are not available at all medical laboratories while methods for measuring the ...
Liselotte Onelöv, Mojca Božič-Mijovski, Alenka Mavri   +2 more
doaj   +1 more source